Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia
INTRODUCTION:Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme converting glutamate into γ-aminobutyric acid. Impaired GAD function can alter motor, cognitive, and behavioral function. Anti-GAD antibodies (GADAbs) can cause several neurological disorders. However, the association between...
Gespeichert in:
| Veröffentlicht in: | The Neurologist (Baltimore, Md.) Md.), 2012-03, Vol.18 (2), p.88-91 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 91 |
|---|---|
| container_issue | 2 |
| container_start_page | 88 |
| container_title | The Neurologist (Baltimore, Md.) |
| container_volume | 18 |
| creator | Najjar, Souhel Pearlman, Daniel Zagzag, David Golfinos, John Devinsky, Orrin |
| description | INTRODUCTION:Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme converting glutamate into γ-aminobutyric acid. Impaired GAD function can alter motor, cognitive, and behavioral function. Anti-GAD antibodies (GADAbs) can cause several neurological disorders. However, the association between anti-GADAbs and pure psychosis, without seizures or focal neurological deficits, is not well defined.
CASE REPORT:A 19-year-old woman with recent-onset psychotic disorder was diagnosed with schizophrenia. Brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. Serum anti-GADAb titers were elevated. Brain biopsy showed subcortical gliosis and microglia-macrophage infiltration. The clinical syndrome improved with immune therapy.
CONCLUSIONS:Severe psychosis and mild cognitive decline without other neurological features, meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision diagnostic criteria for schizophrenia, can result from brain inflammation associated with elevated serum anti-GADAbs. |
| doi_str_mv | 10.1097/NRL.0b013e318247b87d |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_923953252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>923953252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3510-b7febc363d57b0cd4b27158aaeccb8128d925ff6b794716d6a7dab5edd102ecf3</originalsourceid><addsrcrecordid>eNpdkMlOwzAQhi0EgrK8AUK5cQrYniROjlWBglQWsZwtLxMaSOJiJyrl6QmigMRhNKPRv0gfIYeMnjBaiNOb-9kJ1ZQBAst5InQu7AYZcQAW8wzEJhkxKpJYFMB2yG4IL5SyIuPJNtnhHDKRQz4i19O671RTmWhsKhudoVFeu_dVrQJG475zqu0q7ewqeli11rsGozuPAYdv-xypED2YefXhFnOPbaX2yVap6oAH671Hni7OHyeX8ex2ejUZz2IDKaOxFiVqAxnYVGhqbKK5YGmuFBqjc8ZzW_C0LDMtikSwzGZKWKVTtJZRjqaEPXL8nbvw7q3H0MmmCgbrWrXo-iALDkUKPOWDMvlWGu9C8FjKha8a5VeSUfnFUQ4c5X-Og-1oXdDrBu2v6QfcX-7S1R368Fr3S_Ryjqru5nIgzUVeQMyHgwKlNB6GUfgEJdiAog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>923953252</pqid></control><display><type>article</type><title>Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Najjar, Souhel ; Pearlman, Daniel ; Zagzag, David ; Golfinos, John ; Devinsky, Orrin</creator><creatorcontrib>Najjar, Souhel ; Pearlman, Daniel ; Zagzag, David ; Golfinos, John ; Devinsky, Orrin</creatorcontrib><description>INTRODUCTION:Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme converting glutamate into γ-aminobutyric acid. Impaired GAD function can alter motor, cognitive, and behavioral function. Anti-GAD antibodies (GADAbs) can cause several neurological disorders. However, the association between anti-GADAbs and pure psychosis, without seizures or focal neurological deficits, is not well defined.
CASE REPORT:A 19-year-old woman with recent-onset psychotic disorder was diagnosed with schizophrenia. Brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. Serum anti-GADAb titers were elevated. Brain biopsy showed subcortical gliosis and microglia-macrophage infiltration. The clinical syndrome improved with immune therapy.
CONCLUSIONS:Severe psychosis and mild cognitive decline without other neurological features, meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision diagnostic criteria for schizophrenia, can result from brain inflammation associated with elevated serum anti-GADAbs.</description><identifier>ISSN: 1074-7931</identifier><identifier>EISSN: 2331-2637</identifier><identifier>DOI: 10.1097/NRL.0b013e318247b87d</identifier><identifier>PMID: 22367838</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Autoimmune Diseases of the Nervous System - diagnosis ; Autoimmune Diseases of the Nervous System - enzymology ; Diagnosis, Differential ; Female ; Glutamate Decarboxylase - deficiency ; Glutamate Decarboxylase - immunology ; Humans ; Schizophrenia - diagnosis ; Schizophrenia - enzymology ; Schizophrenia - immunology ; Young Adult</subject><ispartof>The Neurologist (Baltimore, Md.), 2012-03, Vol.18 (2), p.88-91</ispartof><rights>2012 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3510-b7febc363d57b0cd4b27158aaeccb8128d925ff6b794716d6a7dab5edd102ecf3</citedby><cites>FETCH-LOGICAL-c3510-b7febc363d57b0cd4b27158aaeccb8128d925ff6b794716d6a7dab5edd102ecf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22367838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Najjar, Souhel</creatorcontrib><creatorcontrib>Pearlman, Daniel</creatorcontrib><creatorcontrib>Zagzag, David</creatorcontrib><creatorcontrib>Golfinos, John</creatorcontrib><creatorcontrib>Devinsky, Orrin</creatorcontrib><title>Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia</title><title>The Neurologist (Baltimore, Md.)</title><addtitle>Neurologist</addtitle><description>INTRODUCTION:Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme converting glutamate into γ-aminobutyric acid. Impaired GAD function can alter motor, cognitive, and behavioral function. Anti-GAD antibodies (GADAbs) can cause several neurological disorders. However, the association between anti-GADAbs and pure psychosis, without seizures or focal neurological deficits, is not well defined.
CASE REPORT:A 19-year-old woman with recent-onset psychotic disorder was diagnosed with schizophrenia. Brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. Serum anti-GADAb titers were elevated. Brain biopsy showed subcortical gliosis and microglia-macrophage infiltration. The clinical syndrome improved with immune therapy.
CONCLUSIONS:Severe psychosis and mild cognitive decline without other neurological features, meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision diagnostic criteria for schizophrenia, can result from brain inflammation associated with elevated serum anti-GADAbs.</description><subject>Autoimmune Diseases of the Nervous System - diagnosis</subject><subject>Autoimmune Diseases of the Nervous System - enzymology</subject><subject>Diagnosis, Differential</subject><subject>Female</subject><subject>Glutamate Decarboxylase - deficiency</subject><subject>Glutamate Decarboxylase - immunology</subject><subject>Humans</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - enzymology</subject><subject>Schizophrenia - immunology</subject><subject>Young Adult</subject><issn>1074-7931</issn><issn>2331-2637</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkMlOwzAQhi0EgrK8AUK5cQrYniROjlWBglQWsZwtLxMaSOJiJyrl6QmigMRhNKPRv0gfIYeMnjBaiNOb-9kJ1ZQBAst5InQu7AYZcQAW8wzEJhkxKpJYFMB2yG4IL5SyIuPJNtnhHDKRQz4i19O671RTmWhsKhudoVFeu_dVrQJG475zqu0q7ewqeli11rsGozuPAYdv-xypED2YefXhFnOPbaX2yVap6oAH671Hni7OHyeX8ex2ejUZz2IDKaOxFiVqAxnYVGhqbKK5YGmuFBqjc8ZzW_C0LDMtikSwzGZKWKVTtJZRjqaEPXL8nbvw7q3H0MmmCgbrWrXo-iALDkUKPOWDMvlWGu9C8FjKha8a5VeSUfnFUQ4c5X-Og-1oXdDrBu2v6QfcX-7S1R368Fr3S_Ryjqru5nIgzUVeQMyHgwKlNB6GUfgEJdiAog</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Najjar, Souhel</creator><creator>Pearlman, Daniel</creator><creator>Zagzag, David</creator><creator>Golfinos, John</creator><creator>Devinsky, Orrin</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia</title><author>Najjar, Souhel ; Pearlman, Daniel ; Zagzag, David ; Golfinos, John ; Devinsky, Orrin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3510-b7febc363d57b0cd4b27158aaeccb8128d925ff6b794716d6a7dab5edd102ecf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Autoimmune Diseases of the Nervous System - diagnosis</topic><topic>Autoimmune Diseases of the Nervous System - enzymology</topic><topic>Diagnosis, Differential</topic><topic>Female</topic><topic>Glutamate Decarboxylase - deficiency</topic><topic>Glutamate Decarboxylase - immunology</topic><topic>Humans</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - enzymology</topic><topic>Schizophrenia - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Najjar, Souhel</creatorcontrib><creatorcontrib>Pearlman, Daniel</creatorcontrib><creatorcontrib>Zagzag, David</creatorcontrib><creatorcontrib>Golfinos, John</creatorcontrib><creatorcontrib>Devinsky, Orrin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Neurologist (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Najjar, Souhel</au><au>Pearlman, Daniel</au><au>Zagzag, David</au><au>Golfinos, John</au><au>Devinsky, Orrin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia</atitle><jtitle>The Neurologist (Baltimore, Md.)</jtitle><addtitle>Neurologist</addtitle><date>2012-03</date><risdate>2012</risdate><volume>18</volume><issue>2</issue><spage>88</spage><epage>91</epage><pages>88-91</pages><issn>1074-7931</issn><eissn>2331-2637</eissn><abstract>INTRODUCTION:Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme converting glutamate into γ-aminobutyric acid. Impaired GAD function can alter motor, cognitive, and behavioral function. Anti-GAD antibodies (GADAbs) can cause several neurological disorders. However, the association between anti-GADAbs and pure psychosis, without seizures or focal neurological deficits, is not well defined.
CASE REPORT:A 19-year-old woman with recent-onset psychotic disorder was diagnosed with schizophrenia. Brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. Serum anti-GADAb titers were elevated. Brain biopsy showed subcortical gliosis and microglia-macrophage infiltration. The clinical syndrome improved with immune therapy.
CONCLUSIONS:Severe psychosis and mild cognitive decline without other neurological features, meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision diagnostic criteria for schizophrenia, can result from brain inflammation associated with elevated serum anti-GADAbs.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>22367838</pmid><doi>10.1097/NRL.0b013e318247b87d</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1074-7931 |
| ispartof | The Neurologist (Baltimore, Md.), 2012-03, Vol.18 (2), p.88-91 |
| issn | 1074-7931 2331-2637 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_923953252 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Autoimmune Diseases of the Nervous System - diagnosis Autoimmune Diseases of the Nervous System - enzymology Diagnosis, Differential Female Glutamate Decarboxylase - deficiency Glutamate Decarboxylase - immunology Humans Schizophrenia - diagnosis Schizophrenia - enzymology Schizophrenia - immunology Young Adult |
| title | Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T06%3A59%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glutamic%20Acid%20Decarboxylase%20Autoantibody%20Syndrome%20Presenting%20as%20Schizophrenia&rft.jtitle=The%20Neurologist%20(Baltimore,%20Md.)&rft.au=Najjar,%20Souhel&rft.date=2012-03&rft.volume=18&rft.issue=2&rft.spage=88&rft.epage=91&rft.pages=88-91&rft.issn=1074-7931&rft.eissn=2331-2637&rft_id=info:doi/10.1097/NRL.0b013e318247b87d&rft_dat=%3Cproquest_cross%3E923953252%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=923953252&rft_id=info:pmid/22367838&rfr_iscdi=true |